Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
21.01
-0.91 (-4.15%)
At close: Dec 31, 2025, 4:00 PM EST
20.50
-0.51 (-2.43%)
After-hours: Dec 31, 2025, 7:58 PM EST
Greenwich LifeSciences Employees
As of December 31, 2024, Greenwich LifeSciences had 8 total employees, including 4 full-time and 4 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$2,434,463
Market Cap
291.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | 3 | 100.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLSI News
- 3 days ago - Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 - GlobeNewsWire
- 10 days ago - Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy - GlobeNewsWire
- 17 days ago - Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? - Benzinga
- 17 days ago - Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 - GlobeNewsWire
- 24 days ago - Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 - GlobeNewsWire
- 4 weeks ago - Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date - GlobeNewsWire
- 3 months ago - Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial - GlobeNewsWire
- 3 months ago - Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium - GlobeNewsWire